FDA Approves Rasonque for Advanced Pancreatic Cancer
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Revolution Medicines received FDA approval on Wednesday for daraxonrasib, sold under the brand name Rasonque, making it the first drug to attack a genetic cause of advanced pancreatic cancer
- In the supporting clinical trial, daraxonrasib as a second-line treatment achieved median overall survival of 13.2 months versus 6.7 months on standard chemotherapy
- The clinical trial that read out earlier this year was characterized as "practice-changing" by oncologists
- Andrew Ko, a UCSF oncologist specializing in gastrointestinal cancers, called the approval "transformative" and "the biggest development we've had in pancreas cancer in decades"
Why it matters: Advanced pancreatic cancer patients who fail first-line therapy now have a second-line option that nearly doubles median survival (13.2 vs. 6.7 months). As the first drug to target a genetic driver of the disease, it represents the most significant therapeutic advance in pancreatic cancer in decades, per the UCSF oncologist quoted.
Ask SkimNews
